Multi Antigen Targeted News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results - Dosed first patient in the Company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia - - Completed construction of new in-house cGMP manufacturing facility in Houston to supply MultiTAA-specific T cell products, including MT-401, for clinical activities and potential commercialization; facility expected to be fully operational in 1H 2021 - News provided by Share this article Share this article HOUSTON, March 9, 2021 /PRNewswir...

Share this article Share this article HOUSTON, Jan. 13, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has completed the construction and qualification of its cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport. The facility will allow production of MultiTAA-specific T cell products according to U.S. Food and Dru...